Skip to content

NeuroClem

Active Private limited companyfounded 2025active for 1 yearDigue des Peupliers 71B, 7000 MonsKBO/BCE: BE 1026.784.293

Lifetime

1 annual account with figures
peak of €6,062 in 2025
€6,062 
peak of €3,736 in 2025
€3,736 
peak of €6,736 in 2025
€6,736 
€8,748 
Board1 name since 2025
1 director
Documentsfilings and deeds
16-06-202645 days before the deadline
2025micro format
Incorporation 27-081 establishment registeredFirst year with figures

Key points

from the 2025 annual accounts

Turnover

≈ €37,000 estimated

The micro format states no turnover.

Position in the sector

€6,736

Less equity than 89% of companies in human health. The sector median is €125,188, over 21,399 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 11,280 companies had the same profile as NeuroClem has now. Each dot stands for 29 companies, two years later.

96.6%
were still trading
2.6%
stopped another way
0.8%
went bankrupt
  • Micro
  • under 2 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 11,280 companies, not a prediction for NeuroClem. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 25-08-2025
  • 300 sharesdeed of 27-08-2025
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:1026784293
Incorporation Founding capital of €3,000, 300 shares · appointed as director · Registered office in the articles: Digue des Peupliers, 71/B 4.8, 7000 Mons · published on 27-08-2025 · Gazette deed
First establishment Digue des Peupliers 71, Mons
All 4 events

Comparable companies

same main activity, similar in size and age
Company
NeuroClem Mons €15,484 €6,062 43.5% -
Dokter Robin Glorieux Leuven €14,912 €5,581 44.2% -
époché Heers €14,313 €5,455 49.4% -
CARDIO CITA Modave €13,270 €6,766 39.2% -
Dr. Tybault Hollanders Neurochirurg Oosterzele €16,820 €5,045 46.7% -
Umamed Destelbergen €17,042 €4,775 51.2% -
Dr. Marjolein De Decker Rumst €20,847 €6,398 38.8% -

These companies have the same main activity as NeuroClem: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €13,300 and €20,800, founded in 2025.

Official details

Source: KBO
Status
Active since 25-08-2025Normal situation
Registered office
10 active companies are registered at this addressOf these, 1 started in the 12 months before 22 November 2026. Source: KBO register, as of 22 November 2026.
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.378.146.3277000 Mons, since 25-08-2025
Financial year end
31 December
Peppol
Reachable since 22-10-2025
Company details

Annual accounts 2025

€15,484
Filing
Filed on 16-06-2026, 45 days before the end of the filing period
Financials

Insights on NeuroClem

NeuroClem has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6,736 and a net result of €3,736.

Its solvency ranks better than 34% of 21,397 sector peers (NACE 86) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about NeuroClem

What is the company number of NeuroClem?
The company number of NeuroClem is 1026.784.293. The VAT number is the same number with BE in front: BE 1026.784.293.
Where is NeuroClem based?
The registered office is at Digue des Peupliers 71B, 7000 Mons.Company details
What does NeuroClem do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of NeuroClem?
NeuroClem is a private limited company (BV).
When was NeuroClem founded?
NeuroClem was founded on 25-08-2025.
Is NeuroClem still active?
Yes, NeuroClem is an active enterprise in the KBO register.
What is the turnover of NeuroClem?
The turnover in financial year 2025 is about €37,000. This figure is estimated from the gross margin of €6,062 and 52 comparable companies (NACE 86). It probably lies between €26,000 and €66,000. It is a rough estimate.Financials
Is NeuroClem profitable?
In financial year 2025, NeuroClem made a profit of €3,736.
Where can I find the annual accounts of NeuroClem?
NeuroClem filed 1 annual account with the National Bank of Belgium, for financial year 2025.
When are the next annual accounts of NeuroClem due?
NeuroClem must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.